OSE Immunotherapeutics : FY 2023 results contained no surprises - decisive results for lusvertikimab at mid-year
>Financial visibility out to 2026 - OSE reported its FY 2023 results yesterday after market close The operating loss will be € 23.0m, compared with € 18.4m in 2022, impacted in particular by a fall in sales to € 2.2m in 2023 from €1 8.3m in 2022. R&D costs are down to €17.2m (vs € 26.9m in 2022), followed by G&A at € 6.0m (vs € 6.7m in 2022). On the balance sheet, cash and cash equivalents at end-December 2023 were € 18.7m (vs € 25.6m in 2022). Including the $ 4...Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.